2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)nicotinic acid | 1219130-08-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)nicotinic acid
• 英文别名: 2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyridine-3-carboxylic acid
• CAS: 1219130-08-1
• 化学式: C₁₂H₁₅NO₅
• 分子量: 253.255
• InChiKey: FKRCGPLCZBPVIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  77.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-溴烟酸 、 丙酮缩甘油 在 sodium hydride 作用下， 以 1,4-二氧六环 为溶剂， 以48%的产率得到2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)nicotinic acid
  参考文献：
  名称：

  [EN] PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS
  [FR] PYRIDINE, PYRIDINE BICYCLIQUE ET ANALOGUES ASSOCIÉS EN TANT QUE MODULATEURS DE SIRTUINE

  摘要：

  本发明提供了新颖的调节sirtuin的化合物以及其使用方法。这些调节sirtuin的化合物可用于延长细胞寿命，并用于治疗和/或预防与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块障碍、炎症、癌症、潮红以及需要增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物与另一治疗剂组合的组合物。这些化合物的一般化学式为（III），其中R1、R2、R"、X、Y、W、Z1和Z2如规范中定义。

  公开号：

  WO2010056549A1

文献信息

• QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS
  申请人：Vu Chi B.

  公开号：US20110306612A1

  公开（公告）日：2011-12-15

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和障碍，包括与衰老或压力有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物和另一种治疗剂的组合物。
• PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS
  申请人：Narayan Radha

  公开号：US20110263564A1

  公开（公告）日：2011-10-27

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新型的调节sirtuin的化合物及其使用方法。这些sirtuin调节化合物可用于延长细胞寿命，治疗和/或预防各种疾病和障碍，包括与衰老或压力相关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。此外，还提供了包含sirtuin调节化合物与另一种治疗剂联合使用的组合物。
• CHROMENONE ANALOGS AS SIRTUIN MODULATORS
  申请人：Oalmann Christopher

  公开号：US20110257174A1

  公开（公告）日：2011-10-20

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的调节sirtuin的化合物及其使用方法。这些sirtuin调节化合物可用于延长细胞寿命，治疗和/或预防各种疾病和障碍，包括与衰老或压力相关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗剂组合的组合物。
• [EN] SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS<br/>[FR] AZAHÉTÉROCYCLES BICYCLIQUES SUBSTITUÉS ET ANALOGUES COMME MODULATEURS DE LA SIRTUINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013059587A9

  公开（公告）日：2014-10-23
• SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline LLC

  公开号：EP2768509B1

  公开（公告）日：2017-03-22